Abstract | PURPOSE:
NAFLD is a hepatic component of type 2 diabetes mellitus (T2D), in which impaired hepatic glucose production plays an important role. Inhibitors of sodium glucose transporter 2 (SGLT2) reduce glycemia and exert beneficial effects on diabetic complications. Recently, dual SGLT1/2 inhibition has been proposed to be more effective in reducing glycemia. We hypothesized that improving hepatic glucose metabolism induced by SGLT1/2 inhibition could be accompanied by beneficial effects on NAFLD progression. METHODS: Glycemic homeostasis, hepatic glucose production and NAFLD features were investigated in obese T2D mice, treated with SGLT1/2 inhibitor phlorizin for 1 week. RESULTS: CONCLUSION:
NAFLD accompanies altered hepatic glucose metabolism in T2D mice and that greatly ameliorated through short-term treatment with the dual SGLT1/2 inhibitor. This suggests that altered hepatic glucose metabolism participates in T2D-related NAFLD and highlights the pharmacological inhibition of SGLTs as a useful approach not only for controlling glycemia but also for mitigating development and/or progression of NAFLD.
|
Authors | Aline David-Silva, João Victor Esteves, Mychel Raony P T Morais, Helayne Soares Freitas, Telma Maria Zorn, Maria Lucia Correa-Giannella, Ubiratan Fabres Machado |
Journal | Diabetes, metabolic syndrome and obesity : targets and therapy
(Diabetes Metab Syndr Obes)
Vol. 13
Pg. 739-751
( 2020)
ISSN: 1178-7007 [Print] New Zealand |
PMID | 32231437
(Publication Type: Journal Article)
|
Copyright | © 2020 David-Silva et al. |